Clinical Trial Update: ABEMA Alone or in COMBO With MK-6482 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating ABEMA (abemaciclib) alone or in combination with MK-6482 (belzutifan) in patients with Clear cell renal cell carcinoma has completed, a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• ABEMA (abemaciclib)
• MK-6482 (belzutifan)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Clear Cell Renal Cell Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2025-07-25